Siga Technologies Inc.

SIGA Healthcare Drug Manufacturers Specialty & Generic

Siga Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $94.6 million, down 31.8% from fiscal 2024.

Revenue
−49.5%
EPS
−66.0%
Free cash flow
−76.0%

Quarter to June 2026, against a year earlier

3.10 0.13 +4.38%
Market cap
$213.4M
P/E
0.0×
Fwd P/E
60.8×
Dividend yield
0.00%
F-score
5/9
Altman Z
14.28
Beneish M
−4.02
Dividend safety
36/100

Siga Technologies Inc. (SIGA) P/E ratio

Alert me on P/E ratio

Siga Technologies Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 102× (August 2020) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 18.3× 149.37%
FY2024 7.3× 20.20%
FY2023 6.1× (59.66%)
FY2022 15.1× 87.37%
FY2021 8.1× (20.11%)
FY2020 10.1× —
FY2019 0.0× —
FY2018 1.5× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 18.4× 0.94%
Dec 2025 18.3× 106.60%
Sep 2025 8.8× 55.26%
42 more quarters

Against its own ten years

Low 0.0× High 102×
Ten-year median 5.1×
Current reading's percentile 41

P/E ratio against peers

Company P/E ratio
EBS Emergent Biosolutions Inc. compare n/m
SIGA Siga Technologies Inc. n/m
ADCT ADC Therapeutics SA compare n/m
BIOA BioAge Labs, Inc. compare n/m
GLAS Glass House Brands Inc. compare n/m
ANIK Anika Therapeutics Inc. compare n/m
AKBA Akebia Therapeutics, Inc. compare n/m
CGC Canopy Growth Corporation compare n/m
LFCR Lifecore Biomedical, Inc. compare n/m
Drug Manufacturers Specialty & Generic industry median 20.5×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on SIGA